-
弥漫性大B细胞淋巴瘤(DLBCL)是世界范围内最常见的非霍奇金淋巴瘤(NHL),占所有NHL病例的30%~40%。DLBCL年发病率8/10万,近年来其发病率有逐渐增加的趋势[1]。虽然化疗及免疫疗法改善了DLBCL病人的总体缓解率,延长病人的无进展生存时间和总生存时间,但仍有约30%病人出现疾病复发或难治,预后不良[2]。因此有必要深入研究DLBCL发生发展的分子机制,寻找有效的诊断治疗靶点。微小RNA(miR)是长度为18~25个核苷酸的RNA分子,可结合靶基因mRNA的3′非翻译区(UTR),调控靶基因蛋白表达,影响细胞的胚胎发育、血管生成、细胞分化及增殖和凋亡等过程。在肝癌[3]、乳腺癌[4]等多种肿瘤中均存在多种miR的异常表达,通过调控下游癌基因及抑癌基因表达影响肿瘤的发生发展的过程。人类miR-17-5p基因位于染色体13q31.3,是miR-17家族成员之一。miR-17-5p作为一种癌基因,可通过调控多种癌基因,如c-MYC的表达,激活丝裂原激活的蛋白激酶途径等机制,发挥促进肿瘤细胞增殖、凋亡抑制及促进肿瘤浸润转移的作用[5]。磷酸酶张力蛋白同系物(PTEN)基因位于人类染色体10q23.31上,该基因编码蛋白具有特异性磷酸酯酶的活性,负性调节磷脂酰肌醇3激酶(PI3K)的信号转导,抑制肿瘤细胞的无限增殖及迁移能力[6]。研究[7]表明,PTEN是miR-17-5p潜在作用靶点,即miR-17-5p可能通过抑制PTEN的表达发挥肿瘤促进的作用。但目前在DLBCL中miR-17-5p及PTEN的表达及临床意义尚不清楚,本研究通过检测癌组织中miR-17-5p及PTEN表达,探讨两者在DLBCL发生发展中的作用及临床意义。现作报道。
-
肿瘤组织中miR-17-5p的相对表达量(5.415±0.486)高于正常组织(1.235±0.210)(t=45.48,P < 0.01);肿瘤组织中PTEN的相对表达量(0.547±0.131)低于正常组织(1.220±0.201)(t=20.67,P < 0.01)。Pearson线性相关分析结果表明,肿瘤组织中miR-17-5p与PTEN的表达呈负相关(r=-0.612,P < 0.01)。
-
病人肿瘤原发部位为节内、LDH≤245 U/L、临床分期为Ⅰ~Ⅱ期miR-17-5p表达高于节外、LDH>245 U/L、Ⅲ~Ⅳ期,PTEN表达低于节外、LDH>245、Ⅲ~Ⅳ期,差异均有统计学意义(P < 0.05~P < 0.01),不同性别、年龄、组织学分类、B2M、分子分型、Hans分型及IPI评分病人,miR-17-5p、PTEN表达差异无统计学意义(P>0.05)(见表 1)。
临床病理特征 n miR-17-5p PTEN 性别 男 43 5.460±0.488 0.541±0.130 女 39 5.365±0.481 0.554±0.132 t — 0.89 0.45 P — >0.05 >0.05 年龄/岁 ≤60 44 5.435±0.489 0.544±0.129 >60 38 5.392±0.482 0.551±0.134 t — 0.40 0.24 P — >0.05 >0.05 组织学分类 中心母细胞型 48 5.420±0.487 0.549±0.130 免疫母细胞型 18 5.413±0.486 0.546±0.129 其他 16 5.402±0.483 0.542±0.128 F — 0.02 0.03 P — >0.05 >0.05 MS组内 — 0.236 0.017 原发部位 结内 69 5.319±0.482 0.562±0.133 结外 13 5.924±0.489 0.447±0.127 t — 4.14 2.88 P — < 0.01 < 0.01 LDH/(U/L) ≤245 40 5.136±0.480 0.595±0.135 >245 42 5.681±0.491 0.501±0.129 t — 5.08 3.22 P — < 0.01 < 0.01 B2M/(mg/L) ≤3 50 5.420±0.487 0.541±0.130 >3 32 5.407±0.485 0.556±0.132 t — 0.12 0.51 P — >0.05 >0.05 临床分期 Ⅰ~Ⅱ期 40 4.787±0.480 0.564±0.135 Ⅲ~Ⅳ期 45 5.612±0.491 0.495±0.127 t — 7.81 2.43 P — < 0.01 < 0.05 IPI评分/分 0~2 53 5.404±0.483 0.551±0.133 3~4 29 5.435±0.488 0.540±0.130 t — 0.28 0.36 P — >0.05 >0.05 Hans分型 GCB 13 5.411±0.490 0.551±0.137 非GCB 69 5.416±0.485 0.546±0.130 t — 0.03 0.13 P — >0.05 >0.05 分子分型 生发中心型 31 5.423±0.489 0.554±0.140 非生发中心型 51 5.410±0.485 0.543±0.135 t — 0.12 0.35 P — >0.05 >0.05 表 1 不同临床病理特征病人肿瘤组织中miR-17-5p、PTEN表达(x±s)
-
SU-DHL-8细胞系转染miR-17-5p抑制剂和抑制剂对照48 h后,PCR检测miR-17-5p和PTEN mRNA表达,结果与转染抑制剂对照相比,转染miR-17-5p抑制剂的SU-DHL-8细胞miR-17-5p表达较低(5.212±0.475和1.012±0.181,t=26.13,P < 0.01),而PTEN表达较高(0.503±0.136和1.890±0.211,t=17.47,P < 0.01)。MTT增殖实验中,与转染抑制剂对照相比,转染miR-17-5p抑制剂的SU-DHL-8细胞在第96小时增殖能力均明显下降(P < 0.01)(见表 2)。Transwell小室实验中,与转染抑制剂对照组细胞穿膜细胞数(71.5±10.6)比较,转染miR-17-5p抑制剂组(50.3±7.6)明显减少(t=3.63,P < 0.05)。
分组 0 h 48 h 72 h 96 h 抑制剂组 0.73±0.12 1.12±0.26 1.97±0.39 2.25±0.36 抑制剂对照组 0.71±0.13 1.35±0.28 2.19±0.41 3.16±0.44 t 0.25 1.35 0.87 3.58 P >0.05 >0.05 >0.05 < 0.01 表 2 各组细胞增殖能力(吸光度)比较(x±s)
-
以miR-17-5p的平均数5.415为截点,分为高miR-17-5p表达组和低表达组,3年总体生存率(OS)分别为42.5%(17/40)、71.4%(30/42),Kaplan-Meier分析(log-rank检验)表明高miR-17-5p组病人3年OS低于低miR-17-5p表达组病人,差异有统计学意义(χ2=3.87,P < 0.05)。以PTEN平均数0.547为截点,高PTEN表达组41例,低PTEN表达组41例,3年OS分别为37.5%(15/41)、78.0%(32/41),低PTEN表达组病人病人3年OS低于高PTEN表达组病人,差异有统计学意义(χ2=6.12,P < 0.05)(见图 1)。
miR-17-5p及PTEN在弥漫性大B细胞淋巴瘤中的表达及其意义
Expression and significance of miR-17-5p and PTEN in diffuse large B-cell lymphoma
-
摘要:
目的研究弥漫大B细胞淋巴瘤(DLBCL)中微小RNA(miR)-17-5p及磷酸酶张力蛋白同系物(PTEN)表达及其临床意义。 方法应用荧光实时定量PCR检测82例DLBCL肿瘤组织及30例淋巴结反应性增生组织(对照组)中miR-17-5p及PTEN的表达,统计学分析组间表达差异及两者与临床病理特征之间的关系。根据miR-17-5p序列合成miR-17-5p抑制剂和抑制剂对照,并转染至DLBCL细胞系中,MTT细胞增殖实验及Transwell小室实验观察对肿瘤细胞增殖和侵袭能力的影响。采用Kaplan-Meier生存分析观察不同miR-17-5p及PTEN的表达水平与病人预后之间的差异。 结果肿瘤组织中miR-17-5p的相对表达量高于正常组织(P < 0.01);肿瘤组织中PTEN的相对表达量低于正常组织(P < 0.01)。Pearson线性相关分析结果表明,肿瘤组织中miR-17-5p与PTEN的表达呈负相关(r=-0.612,P < 0.01)。病人肿瘤原发部位为节内、乳酸脱氢酶(LDH)≤ 245 U/L、临床分期为Ⅰ~Ⅱ期miR-17-5p表达高于节外、LDH>245 U/L、Ⅲ~Ⅳ期,PTEN表达低于节外、LDH>245 U/L、Ⅲ~Ⅳ期,差异均有统计学意义(P < 0.05~P < 0.01)。与转染抑制剂对照相比,转染miR-17-5p抑制剂的SU-DHL-8细胞miR-17-5p表达较低,而PTEN表达较高(P < 0.01)。与转染抑制剂对照相比,转染miR-17-5p抑制剂的SU-DHL-8细胞在第96小时增殖能力均明显下降(P < 0.05);Transwell小室实验中,与转染抑制剂对照组细胞穿膜细胞数比较,转染miR-17-5p抑制剂组明显减少(P < 0.05)。高miR-17-5p组病人3年总生存率低于低miR-17-5p组病人(P < 0.05),低PTEN表达组病人病人3年总生存率低于高PTEN表达组病人(P < 0.05)。 结论DLBCL肿瘤组织中miR-17-5p表达升高,而PTEN表达降低,两者共同参与DLBCL的发生发展过程,有可能成为新的DLBCL诊断和治疗的肿瘤标志物。 -
关键词:
- 弥漫大B细胞淋巴瘤 /
- 微小RNA-17-5p /
- 磷酸酶张力蛋白
Abstract:ObjectiveTo investigate the expression levels of microRNA(miR)-17-5p and phosphotase and tensin homolog(PTEN) in diffuse large B-cell lymphoma(DLBCL), and their clinical significance. MethodsThe expression levels of miR-17-5p and PTEN in 82 cases of DLBCL carcinoma tissues and 30 cases of lymph node reactive hyperplasia tissues(control group) were detected using real-time quantitative PCR.The differences of the expression levels of miR-17-5p and PTEN between groups, and their relationship with clinicopathological features were analyzed.According to miR-17-5p sequence, the miR-17-5p inhibitors and inhibitor controls were synthesized, and transfected into the DLBCL cell lines.The MTT cell proliferation assay and Transwell chamber assay were used to observe the effects on the proliferation and invasion ability of tumor cells.The Kaplan-Meier survival analysis was used to analyze the differences between the different expression levels of miR-17-5p and PTEN and prognosis of patients. ResultsThe relative expression level of miR-17-5p in tumor tissues was higher than that in normal tissues(P < 0.01).The relative expression level of PTEN in tumor tissue was lower than that in normal tissue(P < 0.01).The results of Pearson linear correlation analysis showed that the expression level of miR-17-5p was negatively correlated with the PTEN expression in tumor tissues(r=-0.612, P < 0.01).The expression level of miR-17-5p in patients with primary tumor site locating intra-ganglia, lactic dehydrogenase(LDH) ≤ 245 U/L and clinical stagesⅠ-Ⅱ were higher than that in patients with primary tumor site locating extra ganglia, LDH>245 U/L and clinical stage Ⅲ-Ⅳ, and the expression level of PTEN in patients with primary tumor site locating intra-ganglia, LDH ≤ 245 U/L and clinical stagesⅠ-Ⅱ was lower than that in extra ganglia, LDH>245 and linical stage Ⅲ-Ⅳ(P < 0.05 to P < 0.01).Compared with the transfection inhibitor control, the expression levels of miR-17-5p and PTEN in SU-DHL 8 cells transfected with miR-17-5p inhibitor were lower and higher, respectively(P < 0.01).Compared with the transfection inhibitor control, the proliferation and invasion ability of DLBCL cells transfected with miR-17-5p inhibitor after 96 h was significantly attenuated(P < 0.05).In Transwell chamber assay, the number of transmembrane cells transfected with miR-17-5p inhibitor was significantly reduced compared with the transfection inhibitor control group(P < 0.05).The 3-year overall survival rate of patients with high miR-17-5p was lower than that of patients with low miR-17-5p(P < 0.05), and that of patients with low PTEN expression was lower than that of patients with high PTEN expression(P < 0.05). ConclusionsThe expression level of miR-17-5p increases, while the expression level of PTEN decreases in patients with DLBCL.Both of them are involved in the occurrence and development of DLBCL, and may become a new tumor marker for DLBCL diagnosis and treatment. -
Key words:
- diffuse large B-cell lymphoma /
- miR-17-5p /
- phosphatase tensin
-
表 1 不同临床病理特征病人肿瘤组织中miR-17-5p、PTEN表达(x±s)
临床病理特征 n miR-17-5p PTEN 性别 男 43 5.460±0.488 0.541±0.130 女 39 5.365±0.481 0.554±0.132 t — 0.89 0.45 P — >0.05 >0.05 年龄/岁 ≤60 44 5.435±0.489 0.544±0.129 >60 38 5.392±0.482 0.551±0.134 t — 0.40 0.24 P — >0.05 >0.05 组织学分类 中心母细胞型 48 5.420±0.487 0.549±0.130 免疫母细胞型 18 5.413±0.486 0.546±0.129 其他 16 5.402±0.483 0.542±0.128 F — 0.02 0.03 P — >0.05 >0.05 MS组内 — 0.236 0.017 原发部位 结内 69 5.319±0.482 0.562±0.133 结外 13 5.924±0.489 0.447±0.127 t — 4.14 2.88 P — < 0.01 < 0.01 LDH/(U/L) ≤245 40 5.136±0.480 0.595±0.135 >245 42 5.681±0.491 0.501±0.129 t — 5.08 3.22 P — < 0.01 < 0.01 B2M/(mg/L) ≤3 50 5.420±0.487 0.541±0.130 >3 32 5.407±0.485 0.556±0.132 t — 0.12 0.51 P — >0.05 >0.05 临床分期 Ⅰ~Ⅱ期 40 4.787±0.480 0.564±0.135 Ⅲ~Ⅳ期 45 5.612±0.491 0.495±0.127 t — 7.81 2.43 P — < 0.01 < 0.05 IPI评分/分 0~2 53 5.404±0.483 0.551±0.133 3~4 29 5.435±0.488 0.540±0.130 t — 0.28 0.36 P — >0.05 >0.05 Hans分型 GCB 13 5.411±0.490 0.551±0.137 非GCB 69 5.416±0.485 0.546±0.130 t — 0.03 0.13 P — >0.05 >0.05 分子分型 生发中心型 31 5.423±0.489 0.554±0.140 非生发中心型 51 5.410±0.485 0.543±0.135 t — 0.12 0.35 P — >0.05 >0.05 表 2 各组细胞增殖能力(吸光度)比较(x±s)
分组 0 h 48 h 72 h 96 h 抑制剂组 0.73±0.12 1.12±0.26 1.97±0.39 2.25±0.36 抑制剂对照组 0.71±0.13 1.35±0.28 2.19±0.41 3.16±0.44 t 0.25 1.35 0.87 3.58 P >0.05 >0.05 >0.05 < 0.01 -
[1] CHIAPPELLA A, CASTELLINO A, NICOLOSI M, et al. Diffuse large B-cell lymphoma in the elderly: standard treatment and new perspectives[J]. Expert Rev Hematol, 2017, 10(4): 289. doi: 10.1080/17474086.2017.1305264 [2] KUBUSCHOK B, HELD G, PFREUNDSCHUH M. Management of diffuse large B-cell lymphoma(DLBCL)[J]. Cancer Treat Res, 2015, 165: 271. [3] CUI X, LI Q, HE Y. miR-3117 regulates hepatocellular carcinoma cell proliferation by targeting PHLPPL[J]. Mol Cell Biochem, 2017, 424(1/2): 195. [4] MCGUIRE A, BROWN JA, KERIN MJ. Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring[J]. Cancer Metastasis Rev, 2015, 34(1): 145. doi: 10.1007/s10555-015-9551-7 [5] 吴莹莹, 高波, 丁跃明, 等. miR-17-5p在肿瘤中作用的研究进展[J]. 中国肿瘤临床, 2016, 43(3): 130. doi: 10.3969/j.issn.1000-8179.2016.03.491 [6] JEFFERIES MT, COX AC, SHORNING BY, et al. PTEN loss and activation of K-RAS and β-catenin cooperate to accelerate prostate tumourigenesis[J]. J Pathol, 2017, 243(4): 442. doi: 10.1002/path.4977 [7] 任妮丽, 胡俊华, 吴方毅. miR-17-5p通过靶定PTEN调节结肠癌细胞增殖、侵袭和迁移能力的研究[J]. 解放军医药杂志, 2015(7): 56. doi: 10.3969/j.issn.2095-140X.2015.07.015 [8] HANS CP, WEISENBURGER DD, GREINER TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray[J]. Blood, 2004, 103(1): 275. doi: 10.1182/blood-2003-05-1545 [9] 佟丹江. 弥漫大B细胞淋巴瘤的流行病学分析[J]. 中国现代药物应用, 2016, 10(8): 46. [10] COIFFIER B, SARKOZY C. Diffuse large B-cell lymphoma: R-CHOP failure-what to do?[J]. Hematology Am Soc Hematol Educ Program, 2016(1): 366. [11] ZHANG W, LIN J, WANG P, et al. miR-17-5p down-regulation contributes to erlotinib resistance in non-small cell lung cancer cells[J]. J Drug Target, 2017, 25(2): 125. doi: 10.1080/1061186X.2016.1207647 [12] CHEN C, LU Z, YANG J, et al. MiR-17-5p promotes cancer cell proliferation and tumorigenesis in nasopharyngeal carcinoma by targeting p21[J]. Cancer Med, 2016, 5(12): 3489. doi: 10.1002/cam4.863 [13] LIU L, YANG J, ZHU X, et al. Long noncoding RNA H19 competitively binds miR-17-5p to regulate YES1 expression in thyroid cancer[J]. FEBSJ, 2016, 283(12): 2326. [14] CONKRITE K, SUNDBY M, MUKAI S, et al. miR-17~92 cooperates with RB pathway mutations to promote retinoblastoma[J]. Genes Dev, 2011, 25(16): 1734. doi: 10.1101/gad.17027411 [15] TAN W, LI Y, LIM SG, et al. miR-106b-25/miR-17-92 clusters: polycistrons with oncogenic roles in hepatocellular carcinoma[J]. World J Gastroenterol, 2014, 20(20): 5962. doi: 10.3748/wjg.v20.i20.5962 [16] KECHAGIOGLOU P, PAPI RM, PROVATOPOULOU X, et al. Tumor suppressor PTEN in breast cancer: heterozygosity, mutations and protein expression[J]. Anticancer Res, 2014, 34(3): 1387. [17] NGEOW J, SESOCK K, ENG C. Breast cancer risk and clinical implications for germline PTEN mutation carriers[J]. Breast Cancer Res Treat, 2017, 165(1): 1. doi: 10.1007/s10549-015-3665-z [18] DANKORT D, CURLEY DP, CARTLIDGE RA, et al. Braf(V600E)cooperates with Pten loss to induce metastatic melanoma[J]. Nat Genet, 2009, 41(5): 544. doi: 10.1038/ng.356 [19] TEKCHAM DS, GUPTA S, SHRIVASTAV BR, et al. Epigenetic downregulation of PTEN in gallbladder cancer[J]. J Gastrointest Cancer, 2017, 48(1): 110. doi: 10.1007/s12029-017-9919-8 [20] LI N, MIAO Y, SHAN Y, et al. MiR-106b and miR-93 regulate cell progression by suppression of PTEN via PI3K/Akt pathway in breast cancer[J]. Cell Death Dis, 2017, 18;8(5): e2796. [21] 肖长艳, 郭子健, 曹磊, 等. Mir-106b表达与食管鳞状细胞癌的关系[J]. 南方医科大学学报, 2016, 36(12): 1667. doi: 10.3969/j.issn.1673-4254.2016.12.13 [22] FANG Y, XU C, FU Y. MicroRNA-17-5p induces drug resistance and invasion of ovarian carcinoma cells by targeting PTEN signaling[J]. J Biol Res(Thessalon), 2015, 22: 12.